Annual Report for the financial year 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral Ltd submitted its 31st Annual Report for FY 2024-25, reporting consolidated revenue from operations of ₹70.10 crore, up 28.8% from ₹54.41 crore in FY24. Profit after tax rose to ₹8.10 crore (from ₹6.17 crore), with EPS basic improving to ₹6.89 from ₹5.28, and EBITDA margin holding at 16.5%. The company launched two new strategic ventures — SPL Infusion Pvt Ltd (IV fluids, Pune) and Alevia Healthcare S.R.O. (nutraceuticals, Czech Republic) — which will contribute together with the base business for the first time in FY26. Exports contributed 81.5% of revenue across 25+ countries, with 15 new product launches (taking the portfolio to ~160 products) and entry into 5 new geographies, plus 48 dossier filings in French-speaking Africa. The board declared its first-ever dividend of ₹0.50 per share (5%), and 1,97,394 warrants were converted into equity shares during the year.
Strong double-digit revenue and profit growth, geographic diversification, and the entry into IV fluids and European nutraceuticals mark a meaningful scale-up phase. The maiden dividend and rising EPS are positive signals for shareholders, though margin pressure from freight costs and competitive pricing in new markets remains a near-term watchpoint.